Lilly Has $2.4 Mln Loss on Tax Costs; Sales Rise 5% (Correct)

... Bloomberg.com: Top Worldwide Updated: New York: Jan 26 15:00London: Jan 26 20:00Tokyo: Jan 27 05:00 : Top Worldwide Top Worldwide Regions Markets Economy/Politics Commentary Sports Culture RESOURCES: Bloomberg TV Bloomberg Radio Markets Top Worldwide E-Mail This Story Printer-Friendly Format Pfizer, Drugmakers Losing Republican Support to Prevent Legal Drug Imports U.S.

Stocks Advance for Second Day as Texas Instruments, Lilly Shares Gain Altria's Net Income Declines 6.9 Percent; Sales Gain Amid Dollar's Drop Lilly Has $2.4 Mln Loss on Tax Costs; Sales Rise 5% (Correct) Listen Lilly Has $2.4 Mln Loss on Tax Costs; Sales Rise 5% (Correct) (Corrects seventh paragraph to add dropped word.) By Kerry Dooley Jan.

26 (Bloomberg) - Eli Lilly & Co.

had a fourth-quarter loss on taxes to return $8 billion in profits to the U.S.

from abroad.

Sales rose 5 percent, boosted by the attention-deficit drug Strattera and the cancer treatment Gemzar.

The net loss of $2.4 million, Lilly's first in seven years, was less than a cent a share and compared with net income of $747.2 million, or 69 cents, a year earlier.

The recent quarter included $465 million in tax costs on overseas profits being brought to the U.S.

under a one-year tax holiday, the Indianapolis-based company said in a statement today.

Newer medicines such as Strattera,

Lilly Has $2.4 Mln Loss on Tax Costs; Sales Rise 5% (Update4)

... Bloomberg.com: Top Worldwide Updated: New York: Jan 26 14:00London: Jan 26 19:00Tokyo: Jan 27 04:00 : Top Worldwide Top Worldwide Regions Markets Economy/Politics Commentary Sports Culture RESOURCES: Bloomberg TV Bloomberg Radio Markets Top Worldwide E-Mail This Story Printer-Friendly Format Pfizer, Drugmakers Losing Republican Support to Prevent Legal Drug Imports U.S.

Stocks Advance for Second Day as Texas Instruments, Lilly, Kodak Gain Altria's Net Income Declines 6.9 Percent; Sales Gain Amid Dollar's Drop Lilly Has $2.4 Mln Loss on Tax Costs; Sales Rise 5% (Update4) Jan.

26 (Bloomberg) - Eli Lilly & Co.

had a fourth-quarter loss on taxes to return $8 billion in profits to the U.S.

from abroad.

Sales rose 5 percent, boosted by the attention-deficit drug Strattera and the cancer treatment Gemzar.

The net loss of $2.4 million, Lilly's first in seven years, was less than a cent a share and compared with net income of $747.2 million, or 69 cents, a year earlier.

The recent quarter included $465 million in tax costs on overseas profits being brought to the U.S.

under a one-year tax holiday, the Indianapolis-based company said in a statement today.

Newer medicines such as Strattera, Chief Executive Officer Sidney Taurel has closed sales offices, made plans to cut 1,000 jobs and invested in a new s...

New Drugs Lift Lilly

... New Drugs Lift Eli Lilly QUOTES & SEARCH Quotes Search Site Advanced Search MY STOCKWATCH Select your StockWatch HOT NEWS Analyst ActionsLatest Stories NEWS AND ANALYSIS Tech StocksMarkets ETFs Small Business CommentaryPersonal FinanceThe Good LifeCompany NewsOptions and Futures FEATURED OFFERS Free MembershipAction Alerts PLUSStocks Under $10The Short AdvisorDividend Stock AdvisorThe Trading ReportsCramer RadioCramer's BooksTheStreet.com Value InvestorTelecom ConnectionDaily Swing TradeThe Tech EdgeChartman's Top StocksRealMoney Free TrialBrokersInstitutions CUSTOMER SERVICE Account InfoPasswordLogoutRSS ABOUT US LettersInvestor RelationsCorrections RESEARCH/TOOLS Earnings ReportsMutual Fund FinderStreaming QuotesEconomic CalendarInternet Index Stock News : Robert Steyer New Drugs Lift Eli Lilly By Robert SteyerTheStreet.com Staff Reporter 1/26/2005 11:17 AM EST Click here for more stories by Robert Steyer Updated from 8:15 a.m.

EST Eli Lilly (LLY:NYSE - news - research) Wednesday posted solidly higher fourth-quarter net income, excluding a big one-time tax charge and restructuring costs, as it edged past analysts' EPS estimates thanks to its latest generation of drugs.

Excluding items, net income rose 13% to $814.3 million, or 75 cents a share, vs.

$723.3 million, or 67 cents a share, a year ago.

Analysts were expecting 74 cents a share, according to Thomson First Call.

The news was good enough to send the stock up $1.95, or 3.6%, to $56.80.

Including one-time ...

1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 | 49 | 50 | 51 | 52 | 53 | 54 | 55 | 56 | 57 | 58 | 59 | 60 | 61 | 62 | 63 | 64 | 65 | 66 | 67 | 68 | 69 | 70 | 71 | 72 | 73 | 74 | 75 | 76 | 77 | 78 | 79 | 80 | 81 | 82 | 83 | 84 | 85 | 86 | 87 | 88 | 89 | 90 | 91 | 92 | 93 | 94 | 95 | 96 | 97 | 98 | 99 | All news